IS4398A - New oral oral formulations containing magnesium salt of omeprazole - Google Patents

New oral oral formulations containing magnesium salt of omeprazole

Info

Publication number
IS4398A
IS4398A IS4398A IS4398A IS4398A IS 4398 A IS4398 A IS 4398A IS 4398 A IS4398 A IS 4398A IS 4398 A IS4398 A IS 4398A IS 4398 A IS4398 A IS 4398A
Authority
IS
Iceland
Prior art keywords
oral
omeprazole
formulations containing
magnesium salt
containing magnesium
Prior art date
Application number
IS4398A
Other languages
Icelandic (is)
Inventor
Inga Bengtsson Siv
Ingmar Lövgren Kurt
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of IS4398A publication Critical patent/IS4398A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IS4398A 1994-07-08 1996-12-17 New oral oral formulations containing magnesium salt of omeprazole IS4398A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9400679 1994-07-08
PCT/SE1995/000816 WO1996001622A1 (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole

Publications (1)

Publication Number Publication Date
IS4398A true IS4398A (en) 1996-12-17

Family

ID=20393105

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4398A IS4398A (en) 1994-07-08 1996-12-17 New oral oral formulations containing magnesium salt of omeprazole

Country Status (15)

Country Link
EP (1) EP0768872A1 (en)
KR (1) KR970704426A (en)
BR (1) BR9508261A (en)
CA (1) CA2193681A1 (en)
CZ (1) CZ379596A3 (en)
EE (1) EE03378B1 (en)
FI (1) FI970058L (en)
HU (1) HUT78132A (en)
IS (1) IS4398A (en)
MX (1) MX9700152A (en)
NO (1) NO970036L (en)
NZ (1) NZ289958A (en)
PL (1) PL181265B1 (en)
SK (1) SK281803B6 (en)
WO (1) WO1996001622A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5900258A (en) * 1996-02-01 1999-05-04 Zeolitics Inc. Anti-bacterial compositions
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704869D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9802973D0 (en) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
EP1263445A1 (en) * 2000-03-09 2002-12-11 Ian Whitcroft Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin, metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1552833B1 (en) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1755566A2 (en) * 2004-06-15 2007-02-28 Teva Pharmaceutical Industries Ltd Stable pharmaceutical formulations of benzimidazole compounds
CN105106168B (en) * 2015-08-19 2018-03-06 德州德药制药有限公司 A kind of esomeprazole magnesium intestines capsule and preparation method thereof
WO2022144785A1 (en) * 2020-12-30 2022-07-07 Hk Inno.N Corporation Pharmaceutical composition comprising tegoprazan and non-steroidal anti-inflammatory drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (en) * 1988-05-18 1995-07-26 エーザイ株式会社 Oral formulation of acid labile compounds
SE9302395D0 (en) * 1993-07-09 1993-07-09 Ab Astra NEW PHARMACEUTICAL FORMULATION
SE9302396D0 (en) * 1993-07-09 1993-07-09 Ab Astra A NOVEL COMPOUND FORM

Also Published As

Publication number Publication date
HUT78132A (en) 2000-06-28
WO1996001622A1 (en) 1996-01-25
FI970058A7 (en) 1997-01-07
EE9700014A (en) 1997-06-16
EE03378B1 (en) 2001-04-16
EP0768872A1 (en) 1997-04-23
PL318464A1 (en) 1997-06-09
NO970036D0 (en) 1997-01-06
FI970058A0 (en) 1997-01-07
WO1996001622A8 (en) 1999-12-23
NO970036L (en) 1997-01-06
AU695723B2 (en) 1998-08-20
PL181265B1 (en) 2001-06-29
BR9508261A (en) 1997-12-23
SK281803B6 (en) 2001-08-06
FI970058L (en) 1997-01-07
SK166096A3 (en) 1997-09-10
AU2994795A (en) 1996-02-09
NZ289958A (en) 1998-09-24
HU9700039D0 (en) 1997-02-28
CA2193681A1 (en) 1996-01-25
KR970704426A (en) 1997-09-06
MX9700152A (en) 1997-04-30
CZ379596A3 (en) 1997-08-13

Similar Documents

Publication Publication Date Title
DK0936913T3 (en) Oral pharmaceutical composition containing ibandronate
ATE260659T1 (en) MEDICINAL COMPOSITIONS CONTAINING LEVOSIMENDAN FOR ORAL APPLICATION
ATE284695T1 (en) ORAL MEDICINAL COMPOSITION CONTAINING 2-METHYL-THIENOBENZODIAZEPINE
DK1674084T3 (en) Prolonged release of oral dosage composition
DK0922386T3 (en) Controlled release compositions
IS2976B (en) Oral oral preparation containing tolterodine and controlled release
ID19097A (en) ORAL COMPOSITIONS
HUP9902271A3 (en) Casting form for casting of base of dentistry modell
EE03378B1 (en) Oral dosage form containing magnesium salt of omeprazole
HUP0103257A3 (en) Medicaments containing novel salt form of pantoprazole
DE69838730D1 (en) COMPOSITION FOR DENTAL COATING
ITMI982222A0 (en) ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING BUPRENERPHINE
DE69837668D1 (en) SOLID COMPOSITIONS TO REDUCE DENTAL EXPOSURE
ATE223705T1 (en) FORMULATIONS CONTAINING RAPAMYCIN FOR ORAL ADMINISTRATION
BR9509565A (en) Oral compositions for prolonged release of cisapride
PT906101E (en) FORMULATIONS OF PROLONGED LIBERATION CONTAINING MIZOLASTIN
DK0831820T3 (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
DE69825193D1 (en) Oral administration compositions containing pyridazinone compounds
EE04220B1 (en) Controlled release oral formulations of levosimendan
DE69730763D1 (en) Denture cleaning compositions containing per compounds
ITMI942130A0 (en) PROCEDURE FOR THE PREPARATION OF ORAL COMPOSITIONS CONTAINING QUINOLONES
ID29104A (en) COMPOSITION OF SKIN BLEACH FOR ORAL GIVING
NO180103C (en) Procedure for direct fitting of dentures
NO994140L (en) Pharmaceutical composition for the programmed release of dexfenfluramine
SE9802197D0 (en) Formulations of busulphan